OncoMatch/Clinical Trials/NCT06364007
HAIC Combined With Durvalumab and Tremelimumab and Lenvatinib in uHCC
Is NCT06364007 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies HAIC+STRIDE+Len for hepatocellular carcinoma.
Treatment: HAIC+STRIDE+Len — The treatment options for unresectable HCC have rapidly developed, and immunotherapy has shown significant survival benefits in hepatocellular carcinoma. The STRIDE regimen of Single Tremelimumab (high, priming 300-mg dose) Regular Interval Durvalumab (1500 mg every 4 weeks) improved OS vs sorafenib in pts with unresectable HCC. In Asian region, HAIC is applied for HCC patients who are not suitable for surgical resection or local ablation treatment. Retrospective studies suggested a potent antitumor effect and survival benefit of HAIC plus programmed death-1 inhibitor and Lenvatinib. This phase II study was aimed to evaluate the efficacy and safety of STRIDE plus lenvatinib, given concurrently with HAIC in pts with unresectable HCC.
Check if I qualifyExtracted eligibility criteria
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
Hemoglobin ≥ 90 g / L; ANC ≥ 1.5 × 10^9/L; Platelet count ≥ 75 × 10^9/L
Kidney function
Creatinine ≤ 1.5 × ULN
Liver function
Albumin ≥ 28 g / L; Total bilirubin ≤ 2 × ULN; AST, ALT ≤ 5 × ULN; ALP ≤ 5 × ULN
Cardiac function
INR or PT ≤ 1.5 × ULN; APTT ≤ 1.5 × ULN
Major organs are functioning normally: Hemoglobin ≥ 90 g / L; ANC ≥ 1.5 × 10^9/L; Platelet count ≥ 75 × 10^9/L; Albumin ≥ 28 g / L; Total bilirubin ≤ 2 × ULN; AST, ALT ≤ 5 × ULN; ALP ≤ 5 × ULN; Creatinine ≤ 1.5 × ULN; INR or PT ≤ 1.5 × ULN; APTT ≤ 1.5 × ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify